What are the different thyroid medications, including their classes, dosing regimens, and monitoring requirements for hypothyroidism and hyperthyroidism?

Thyroid Medications: Classes, Dosing, and Monitoring

Medications for Hypothyroidism

Levothyroxine (T4) is the standard first-line treatment for hypothyroidism, administered as a single daily dose on an empty stomach, 30-60 minutes before breakfast. 1

Levothyroxine Dosing Regimens

Initial Dosing:

• Healthy adults <70 years without cardiac disease: Start at full replacement dose of approximately 1.6 mcg/kg/day 1
• Elderly patients (>70 years) or those with cardiac disease: Start at 25-50 mcg/day and titrate gradually by 12.5-25 mcg every 6-8 weeks to avoid precipitating myocardial infarction, heart failure, or arrhythmias 1
• Severe hypothyroidism with cardiac disease: Begin at 25 mcg/day with very slow titration, as rapid normalization can unmask or worsen cardiac ischemia 1

Dose Adjustments:

• Increase by 12.5-25 mcg increments based on TSH response 1
• Smaller increments (12.5 mcg) for elderly or cardiac patients 1
• Larger increments (25 mcg) acceptable for younger patients without cardiac disease 1

Monitoring Requirements for Levothyroxine

During Dose Titration:

• Check TSH and free T4 every 6-8 weeks after any dose adjustment, as this represents the time needed to reach steady state 1
• Free T4 helps interpret ongoing abnormal TSH levels during therapy, as TSH may take longer to normalize 1

Maintenance Monitoring:

• Once stable dose achieved with TSH in target range (0.5-4.5 mIU/L), repeat TSH every 6-12 months 1
• More frequent monitoring if symptoms change or clinical status alters 1

Special Populations:

• Pregnant women: Check TSH every 4 weeks during first half of pregnancy, then at least once in third trimester, as levothyroxine requirements typically increase 25-50% 1
• Patients on immune checkpoint inhibitors: Monitor TSH every 4-6 weeks for first 3 months, then every second cycle 1
• Thyroid cancer patients: Monitoring frequency depends on risk stratification and target TSH suppression goals 1

Target TSH Ranges

Primary Hypothyroidism:

• Target TSH: 0.5-4.5 mIU/L with normal free T4 1
• Avoid TSH suppression <0.1 mIU/L, which increases risk of atrial fibrillation (3-5 fold), osteoporosis, fractures, and cardiovascular mortality 1

Thyroid Cancer Patients (TSH Suppression Therapy):

• Low-risk with excellent response: TSH 0.5-2.0 mIU/L 1
• Intermediate-to-high risk with biochemical incomplete response: TSH 0.1-0.5 mIU/L 1
• Structural incomplete response: TSH <0.1 mIU/L 1

Critical Safety Considerations for Levothyroxine

Before Initiating Therapy:

• Always rule out adrenal insufficiency first, especially in suspected central hypothyroidism, by measuring morning cortisol and ACTH 1
• Starting thyroid hormone before adequate corticosteroid coverage can precipitate life-threatening adrenal crisis 1
• If adrenal insufficiency confirmed, start hydrocortisone (20 mg morning, 10 mg afternoon) at least one week before levothyroxine 1

Common Pitfalls:

• Approximately 25% of patients on levothyroxine are unintentionally maintained on doses sufficient to fully suppress TSH, increasing serious complication risks 1
• Never adjust doses more frequently than every 6-8 weeks before reaching steady state 1
• Do not treat based on single elevated TSH value—30-60% normalize spontaneously on repeat testing 1

Alternative Thyroid Hormone Preparations

Liothyronine (T3):

• Requires twice-daily administration due to short half-life 2
• Serum T3 frequently rises to supranormal values during absorption phase, causing palpitations 2
• Not recommended as monotherapy for hypothyroidism 2

Combination T4/T3 Therapy:

• Some patients with persistent symptoms despite biochemical euthyroidism on T4 alone may benefit from combination therapy 2
• One study showed improved psychometric scores when 50 mcg of T4 was substituted with 12.5 mcg T3 2
• This remains investigational and is not standard practice 2

Desiccated Thyroid:

• Contains both T4 and T3 2
• Serum T3 frequently rises to supranormal values during absorption, associated with palpitations 2
• Not preferred due to inconsistent hormone ratios and absorption issues 2

---

Medications for Hyperthyroidism

Methimazole is the preferred first-line antithyroid drug for hyperthyroidism due to superior efficacy, safety profile, once-daily dosing, and lower cost—except during the first trimester of pregnancy when propylthiouracil is preferred. 3, 4

Antithyroid Drug Classes and Mechanisms

Thionamides:

• Methimazole (MMI) and Propylthiouracil (PTU) inhibit thyroid hormone synthesis at different steps 4, 5
• Primary mechanism: inhibit thyroid peroxidase, blocking iodine organification and coupling reactions 4
• Secondary effects: immunomodulatory properties in Graves' disease 4

Methimazole Dosing and Monitoring

Initial Dosing:

• Start at 10-30 mg as single daily dose 5
• Higher doses (30-40 mg) for severe hyperthyroidism 3

Monitoring Strategy:

• Monitor free T4 or free T3 index every 2-4 weeks during initial treatment 3
• Target: maintain free T4/T3 in high-normal range using lowest effective dose 3
• Do NOT use TSH to guide therapy initially—TSH may remain suppressed for months even after achieving euthyroidism 3

Dose Adjustment Algorithm:

• If free T4/T3 in high-normal range: maintain current dose 3
• If free T4/T3 drops below normal: reduce dose or temporarily discontinue 3
• Never reduce methimazole based solely on suppressed TSH while free T4 remains elevated—this leads to inadequate treatment and recurrent hyperthyroidism 3

Maintenance Therapy:

• Once euthyroid, reduce to lowest effective maintenance dose (typically 5-10 mg daily) 3
• Recent studies support long-term methimazole therapy with low maintenance doses for Graves' disease and toxic multinodular goiter 4

Propylthiouracil Dosing and Monitoring

Initial Dosing:

• Start at 100-300 mg every 6-8 hours (requires multiple daily doses) 5

Indications for PTU Over Methimazole:

• First trimester of pregnancy (weeks 0-16) due to methimazole's association with aplasia cutis and choanal/esophageal atresia 3, 5
• Patients intolerant to methimazole 3
• Thyroid storm (PTU additionally blocks peripheral T4 to T3 conversion) 5

Pregnancy Management:

• Use PTU during pre-pregnancy months and first 16 weeks of gestation 3
• Switch to methimazole after first trimester for remainder of pregnancy 3
• Both drugs compatible with breastfeeding 3

Critical Adverse Effects Monitoring

Agranulocytosis (Most Serious):

• Occurs in 0.1-0.5% of patients, typically within first 3 months 3, 6
• Presents with sore throat and fever 3
• Requires immediate CBC and drug discontinuation 3
• Can be effectively treated with granulocyte colony-stimulating factor 6

Hepatotoxicity:

• More common with PTU than methimazole 3
• Monitor for fever, nausea, vomiting, right upper quadrant pain, dark urine, jaundice 3
• Requires immediate drug discontinuation if suspected 3

Other Serious Reactions:

• Vasculitis: can be life-threatening; watch for skin changes, hematuria, respiratory symptoms 3
• Aplastic anemia, thrombocytopenia (exceedingly rare) 6
• Lupus-like syndrome (rare) 6

Minor Adverse Effects:

• Skin rash, itching, mild leukopenia occur in 3-5% of patients 6
• Usually transient and do not require drug discontinuation 6

---

Adjunctive Medications for Hyperthyroidism

Beta-Blockers for Symptom Control

Indications:

• Provide immediate symptomatic relief for tachycardia, tremor, anxiety while awaiting thyroid hormone normalization 3
• Essential for cardiovascular protection in hyperthyroid patients with cardiac disease 3

Preferred Agents:

• Atenolol: 25-50 mg daily 3
• Propranolol: dose varies, provides additional benefit of blocking peripheral T4 to T3 conversion 3

Dosing Strategy:

• Titrate targeting heart rate <90 bpm if blood pressure allows 3
• Reduce dose once euthyroid state achieved to avoid bradycardia 3

Special Considerations:

• For hyperthyroidism with atrial fibrillation, beta-blockers recommended for rate control unless contraindicated 3
• When beta-blockers cannot be used, non-dihydropyridine calcium channel antagonists (diltiazem or verapamil) are alternatives 3

---

Definitive Treatment Options for Hyperthyroidism

Radioactive Iodine (I-131) Ablation

Contraindications:

• Absolutely contraindicated in pregnancy and breastfeeding 3
• Pregnancy must be avoided for 4 months following administration 3

Risks:

• Potential worsening of Graves' ophthalmopathy 3

Thyroidectomy

• Surgical option for definitive treatment 3
• Requires preoperative preparation with antithyroid drugs to achieve euthyroid state 3

---

Treatment of Subclinical Hyperthyroidism

For TSH <0.1 mIU/L, treatment should be considered, especially in patients >60 years or those with cardiac disease, osteopenia, or osteoporosis risk, due to 3-fold increased risk of atrial fibrillation over 10 years. 3

Treatment Thresholds:

• TSH <0.1 mIU/L: Consider treatment, particularly for:

  • Patients >60 years 3
  • Those with cardiac disease, osteopenia, or osteoporosis 3
  • Estrogen-deficient women (bone loss risk) 3
  • 3-fold increased risk of atrial fibrillation over 10 years 3
  • Up to 3-fold increased cardiovascular mortality in individuals >60 years 3

• TSH 0.1-0.45 mIU/L: Routine treatment not recommended due to insufficient evidence of adverse outcomes 3

  • Consider treatment only in elderly with cardiovascular risk factors 3

---

Special Clinical Scenarios

Destructive Thyroiditis

Management Approach:

• Self-limited condition with biphasic course (hyperthyroid phase followed by hypothyroid phase) 3
• Antithyroid drugs NOT indicated (no active hormone synthesis occurring) 3
• Beta-blockers for symptomatic relief during hyperthyroid phase 3
• Monitor with symptom evaluation and free T4 testing every 2 weeks 3
• Introduce levothyroxine if patient becomes hypothyroid (low free T4/T3, even if TSH not yet elevated) 3

Hyperthyroidism with Atrial Fibrillation

Rate Control:

• Beta-blockers first-line for rate control 3
• Non-dihydropyridine calcium channel antagonists if beta-blockers contraindicated 3

Rhythm Control:

• Thyroid function must be normalized prior to cardioversion to reduce recurrence risk 3
• Antiarrhythmic drugs and cardioversion generally unsuccessful while thyrotoxicosis persists 3
• Never attempt cardioversion without first achieving euthyroid state 3

Anticoagulation:

• Guide by CHA₂DS₂-VASc risk factors, not solely by presence of hyperthyroidism 3

Drug Interactions with Antithyroid Medications

Warfarin:

• Antithyroid drugs increase anticoagulation effect; warfarin dose adjustments required 3

Beta-blockers:

• May need dose reduction when patient becomes euthyroid 3

Theophylline:

• Clearance decreases when patient becomes euthyroid 3

---

Key Monitoring Pearls

For Hypothyroidism:

• TSH is the most sensitive test with >98% sensitivity and >92% specificity 1
• Free T4 assists interpretation when TSH remains abnormal during therapy 1
• Wait 6-8 weeks between dose adjustments for steady state 1

For Hyperthyroidism:

• Use free T4/T3 (not TSH) to guide initial antithyroid drug dosing 3
• TSH may remain suppressed for months after achieving euthyroidism 3
• Monitor for agranulocytosis within first 3 months of thionamide therapy 3